Abordaje terapeútico en el TDAH, TUS y psicosis tóxica

  1. M. P. Ferreira Frías 1
  2. M. S. Geijo Uribe 1
  3. C. Imaz Roncero 1
  4. E. Vásquez Cornieles 1
  1. 1 Hospital Clínico Universitario de Valladolid. Valladolid
Journal:
Revista de Psiquiatría Infanto-Juvenil

ISSN: 2660-7271,  1130-9512

Year of publication: 2012

Volume: 29

Issue: 4

Pages: 56-61

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista de Psiquiatría Infanto-Juvenil

Abstract

Attention deficit hyperactivity disorder (ADHD) is an independent risk factor for the gradual development of substance use disorders (SUD) in adolescence and adult-hood. High rates of ADHD are found in people diagnosed with SUD, who consume different classes of substanc-es, including opioids, alcohol, cannabis, stimulants and nicotine. Thus, prospective longitudinal studies suggest that the diagnosis of ADHD in childhood or adolescence increases the risk of SUD later in adult life. Substance abuse may modify the symptoms, rapidity of progres-sion, response to treatment, and long-term outcome of ADHD. Similarly, ADHD may modify the course of the SUD. This is the reason that we need to diagnose and treat this comorbidity, and have the knowledge of all possible symptoms of psychosis that can emerge in sub-stance abuse and stimulant treatment.

Bibliographic References

  • Biederman J, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998; 44: 269-273.
  • Wilens T, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475-482.
  • Biederman J, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-1658.
  • Biederman, Monuteaux, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45: 408-14.
  • Schiffer et al. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 2006; 59: 243-51.
  • Koob & Nestler. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 1997; 9: 482-97.
  • Wilens T, Faraone S, Biederman J, Gunawardene S. Does stimulant therapy of ADHD be get later substance abuse: A metanalytic review of the literature. Pediatrics 2003; 11: 179-85.
  • J. Graham, T. Banaschewski , J. Buitelaar , D. Coghill , M. Danckaerts, R. W. Dittmann , M. Dopfner et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011; 20: 17-37.
  • Randal G. Ross. Psychotic and Manic-like Symptoms During Stimulant Treatment of Attention Deficit Hyperactivity Disorder. Am J Psychiatry 2006; 163: 1149-1152.
  • Kollins Scott H. ADHD, Substance Use Disorders, and Psychostimulant Treatment: Current Literature and Treatment Guidelines. J Att Dis 2008; 12: 115-125.
Data source: Dialnet